Clinical Trials and Tribulations: Implementation Processes in Schizophrenia Research Outcome

Reference

• Addington, D. The use of placebos in clinical trials for acute schizophrenia. Canadian Journal of Psychiatry (1995) 40:171–176.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION. Industry and academia collaboration in psychiatric research. Psychiatric Research Report (1997) 13: 1,6,9–10,12.
   Google Scholar
• Awad, A. G. Drug therapy in schizophrenia: variability of outcome and prediction of response. Canadian Journal of Psychiatry (1989) 34:711–720.
   PubMed Web of Science ®Google Scholar
• Awad, A. G. Methodological and design issues in clinical trials of new neuroleptics: An overview. British Journal of Psychiatry (1993) 163(Suppl. 22):51–57.
   Google Scholar
• Brabbins, C., Butler, J., and Bentall, R. Consent to neuroleptic medication for schizophrenia: Clinical, ethical and legal issues. British Journal of Psychiatry (1996) 168:540–544.
   PubMed Web of Science ®Google Scholar
• Burke, J. D. Jr., Pincus, H. A., and Pardes, H. The clinician-researcher in psychiatry. American Journal of Psychiatry (1986) 143:968–975.
   PubMed Web of Science ®Google Scholar
• Carpenter, W. T., Schooler, N. R., and Kane, J. M. The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry (1997) 54:401–407.
   PubMed Web of Science ®Google Scholar
• Carpenter, W. T. Jr. Maintenance therapy of persons with schizophrenia. Journal of Clinical Psychiatry (1996) 57(Suppl. 9):10–18.
   PubMedGoogle Scholar
• Dedeyn, P. P. On the ethical acceptability of placebo application in neuropsychiatric research. Acta Neurologica Belgium (1995) 95:8–17.
   PubMed Web of Science ®Google Scholar
• De Groot, J. M., and Kennedy, M. D. Integrating clinical and research psychiatry. Journal of Psychiatry and Neuroscience (1995) 20:150–154.
   PubMed Web of Science ®Google Scholar
• Dimasi, J. A., Grabowski, H. G., and Vernon, J. R&D costs, innovative output and firm size in the pharmaceutical industry. International Journal of the Economics of Business (1995) 2:201–219.
   Google Scholar
• Falloon, I. R. H., Kydd, R. R., Coverdale, J. H., and Laidlaw, T. M. Early detection and intervention for initial episodes of schizophrenia. Schizophrenia Bulletin (1996) 22:271–282.
   PubMed Web of Science ®Google Scholar
• Felker, B., Yazel, J. J., and Short, D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatric Services (1996) 47:1356–1363.
   PubMed Web of Science ®Google Scholar
• Friedman, L. M., Furberg. C. D., and Demets, D. L. Fundamentals of Clinical Trials, 2nd ed.. PSG Publishing, 1985.
   Google Scholar
• Gaebel, W. The importance of non-biological factors in influencing the outcome of clinical trials. British Journal of Psychiatry (1993) 163(Suppl. 22):45–50.
   PubMedGoogle Scholar
• Gallant, D., and Krinsky, S. L. Ethical and legal considerations in drug trials. In R. F. Prien and D. S. Robinson, eds., Clinical Evaluation of Psychotropic Drugs (pp. 261–280). Raven Press, 1994.
   Google Scholar
• Gelenberg, A. J., Frank, E., Keller, M. B., Prien, R. F., and Post, R. M. Evaluating pharmacologic treatments for bipolar disorder. In R. F. Prien and D. S. Robinson, eds., Clinical Evaluation of Psychotropic Drugs (pp. 327–344). Raven Press, 1994.
   Google Scholar
• Goldstein, M. J. Psychosocial strategies for maximizing the effects of psychotropic medications for schizophrenia and mood disorder. Psychopharmacology Bulletin (1992) 28:237–240.
   PubMedGoogle Scholar
• Helmchen, H. Ethical problems and design of controlled clinical problems. In O. Benkert, W. Maier, and K. Rickels, eds., Methodology of the Evaluation of Psychotropic Drugs (pp. 82–87). Springer-Verlag, 1990.
   Google Scholar
• Herz, M. I., Glazer, W. M., Mostert, M. A., Sheard, M. A., Szymanski, H. V., Hafez, H., Mirza, M., and Vana, J. Intermittent vs maintenance medication in schizophrenia: two year results. Archives of General Psychiatry (1991) 48:333–339.
   PubMed Web of Science ®Google Scholar
• Hogan, T. P., and Awad, A. G. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychological Medicine (1992) 22:347–352.
   PubMed Web of Science ®Google Scholar
• Hough, R. L., Tarke, H., Renker, V., Shields, P., and Glatstein, J. Recruitment and retention of homeless mentally ill participants in research. Journal of Consulting and Clinical Psychology (1996) 64:881–891.
   PubMed Web of Science ®Google Scholar
• Kane, J. M. Obstacles to clinical research and new drug development in schizophrenia. Schizophrenia Bulletin (1991) 17:353–356.
   PubMed Web of Science ®Google Scholar
• Kane, J. M. Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics. Psychopharmacology Bulletin (1992) 28:227–229.
   PubMedGoogle Scholar
• Kane, J. M., Schooler, N. R., Marder, S. R., Simpson, G. M., and Casey, D. E. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. R. F. Prien, and D. S. Robinson, eds., Clinical Evaluation of Psychotropic Drugs. Raven Press, 1994.
   Google Scholar
• Keefe, R. S. E., and Harvey, P. D. Understanding Schizophrenia. Free Press, 1994.
   Google Scholar
• Levinson, D. J., and Klerman, G. L. The clinician executive: Some problematic issues for the psychiatrist in mental health organizations. Psychiatry (1967) 30:3–15.
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A. Prediction of outcome in first-episode schizophrenia. Journal of Clinical Psychiatry (1993) 54:13–17.
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A., and Sloan, J. The moral imperatives of medical research in human subjects. Journal of the California Alliance for the Mentally Ill (1994) 5:40–42.
   PubMedGoogle Scholar
• Lima, B. R., and Pai, S. Concurrent medical and psychiatric disorders among schizophrenic and neurotic outpatients. Community Mental Health Journal (1987) 23:30–39.
   PubMed Web of Science ®Google Scholar
• Loebel, A. D., Lieberman, J. A., Alvir, J. M. J., Geisler, S. H., Szymanskii, S. R., and Mayerhoff, D. I. Consistency of treatment response across successive psychotic episodes in recent-onset schizophrenia. Paper presented at the International Congress of Schizophrenia Research, Colorado Springs, CO, April 1993.
   Google Scholar
• Macewan, G. W. New antipsychotic medications: do research results relate to clinical practice? Canadian Journal of Psychiatry (1993) 38(Suppl. 3): S75–S79.
   PubMedGoogle Scholar
• Madakasira, S., and Cain, H. I. Integrating research projects into clinical service settings. Hospital and Community Psychiatry (1988) 39:888–890.
   PubMedGoogle Scholar
• Mason, S. E.African American participation in clinical trials research. Manuscript submitted for publication, 1998.
   Google Scholar
• Mason, S. E., Gingerich, S., and Siris, S. G. Patients' and caregivers' adaptation to improvement in schizophrenia. Hospital and Community Psychiatry (1990) 41:541–544.
   PubMedGoogle Scholar
• Mcglashan, T. H. Early detection and intervention in schizophrenia research. Schizophrenia Bulletin (1996) 22:327–345.
   PubMed Web of Science ®Google Scholar
• Mueser, K. T., and Gingerich, S. Coping With Schizophrenia: A Guide for Families. New Harbinger, 1994.
   Google Scholar
• Orr, R. D. Guidelines for the use of placebo controls in clinical trials of psychopharmacologic agents. Psychiatric Services (1996) 47:1262–1264.
   PubMed Web of Science ®Google Scholar
• Robinson, D., Woerner, M., Pollack, S., and Lerner, G. Subject selection biases in clinical trials: Data from a multicenter schizophrenia treatment study. Journal of Clinical Psychopharmacology (1996) 16:170–176.
   PubMed Web of Science ®Google Scholar
• Schachter, D., Kleinman, I., Prendergast, P., Remington, G., and Schertzer, S. The effect of psychopathology on the ability of schizophrenic patients to give informed consent. Journal of Nervous and Mental Disease (1994) 182:360–362.
   PubMed Web of Science ®Google Scholar
• Schooler, N. R., and Keith, S. J. The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin (1993) 29:431–446.
   PubMedGoogle Scholar
• Siris, S. G., Docherty, J. P., and Mcglashan, T. H. Intrapsychic structural effects of psychiatric research. American Journal of Psychiatry (1979) 136: 1567–1571.
   Web of Science ®Google Scholar
• Spohn, H. E., and Fitzpatrick, T. Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal. Journal of Abnormal Psychology (1980) 89:79–92.
   PubMed Web of Science ®Google Scholar
• Steingard, S., Allen, M., and Schooler, N. R. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Journal of Clinical Psychiatry (1994) 55:470–472.
   PubMed Web of Science ®Google Scholar
• Swanson, C. L. J., Turetsky, B. I., Bilker, W., Gur, R. C., and Gur, R. E. Rater gender and symptom ratings of patients with schizophrenia. Poster presentation at the Sixth International Congress on Schizophrenia Research, Colorado Springs, CO, April 12-16, 1997.
   Google Scholar
• Thompson, E. E., Neighbors, H. W., Munday, C., and Jackson, J. S. Recruitment and retention of African American patients for clinical research: An exploration of response rates in an urban psychiatric hospital. Journal of Consulting and Clinical Psychology (1996) 64:861–867.
   PubMed Web of Science ®Google Scholar
• Torrey, E. F. Surviving Schizophrenia: A Family Manual, rev. ed. Harper and Row, 1988.
   Google Scholar
• Van Putten, T., and May, P. R. A. Subjective response as a predictor of outcome in pharmocotherapy, Archives of General Psychiatry (1978) 35:447–480.
   Google Scholar
• Van Putten, T., Philip, R. A., Marder, S. R., and Wittmann, L. A. Subjective response to antipsychotic drugs. Archives of General Psychiatry (1981) 38:187–190.
   PubMed Web of Science ®Google Scholar
• Viner, M. W., Waite, J., and Thienhaus, O. J. Comorbidity and the need of physical examinations among patients seen in the psychiatric emergency service. Psychiatric Services (1996) 47:947–948.
   PubMed Web of Science ®Google Scholar